Study provides evidence supporting recommended 10 year interval for colonoscopies for most patients

May 23, 2006

Patients with a negative colonoscopy examination have a reduced risk of developing colorectal cancer for more than 10 years, compared to the general population, according to a study in the May 24/31 issue of JAMA.

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer deaths in North America. Screening for CRC and its precursor lesions has become an increasingly prevalent practice. Colonoscopy has been recommended as the preferred initial screening test by several medical organizations and is being widely performed in the United States for screening among average-risk individuals. Colonoscopy allows for removal of most precancerous polyps at the time of detection. A screening interval of 10 years after a normal colonoscopy has been adopted based on the estimate of the time it takes for an adenomatous (benign tumor) polyp to transform into carcinoma. However, the duration over which the risk of CRC remains decreased following the performance of a normal colonoscopy has been unknown.

Harminder Singh, M.D., of the University of Manitoba, Canada, and colleagues analyzed data from individuals who underwent a colonoscopic evaluation that did not result in the diagnosis of colorectal neoplasia to determine the magnitude and duration of their lowered risk of developing CRC. The patients (n = 35,975), who had been evaluated between April 1989 and December 2003, were identified using Manitoba Health's physician billing claims database. Standardized incidence ratios (SIRs) were calculated to compare colorectal cancer incidence in this group with colorectal cancer incidence in the provincial population. The patients were followed up from the time of the colonoscopy until diagnosis of colorectal cancer, death, moving from Manitoba, or end of the study period on December 31, 2003.

The researchers found that a negative colonoscopy was associated with SIRs of 0.69 (31 percent lower incidence of CRC compared to general population) at 6 months, 0.66 (34 percent lower incidence) at 1 year, 0.59 (41 percent lower incidence) at 2 years, 0.55 (45 percent lower incidence) at 5 years, and 0.28 (72 percent lower incidence) at 10 years. The proportion of colorectal cancer located in the right side of the colon was significantly higher in the colonoscopy group than the rate in the Manitoba population (47 percent vs. 28 percent).

"This study demonstrates that following a negative result from a colonoscopy performed in the usual clinical practice, the risk of developing CRC is at most 60 percent to 70 percent of the risk of developing CRC in the general population and the duration of the interval of decreased CRC risk persists for more than 10 years. Furthermore, if an individual undergoes a single negative colonoscopy, excepting any follow-up endoscopies at which CRC is diagnosed, the risk of developing CRC is even lower and the duration of the interval of decreased risk again exceeds the 10-year interval currently recommended between screening colonoscopies. Our findings suggest that screening colonoscopies do not need to be performed at intervals shorter than 10 years," the authors conclude.
-end-
(JAMA. 2006;295:2366-2373. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: For funding/support information, please see the JAMA article.

Editorial: Screening for Colorectal Cancer by Colonoscopy - Adding to the Evidence

In an accompanying editorial, Timothy R. Church, Ph.D., of the University of Minnesota School of Public Health, Minneapolis, comments on the studies in this week's JAMA on colorectal cancer screening.

"The authors of these 2 studies address 2 important questions. Because the population average age is steadily increasing and decisions about screening elderly patients have been made inconsistently and with little reference to data, the attempt to bring a careful analysis to bear is crucial. As colonoscopy becomes more widely used as the primary screening method, it is important to reevaluate the performance of the recommended 10-year screening interval, not only for its effect on clinical outcomes but also on the cost-effectiveness of the screening effort. These 2 analyses are solid attempts to address these unanswered questions. Efforts to get at better answers will no doubt continue."

(JAMA. 2006;295:2411-2412. Available pre-embargo to the media at www.jamamedia.org)

The JAMA Network Journals

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.